UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?

Special Report by Charlotte Yu
Jan.19.2024
UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Without tax (price) incentives and flavor differentiation compared to traditional cigarettes, there would be little motivation for people to quit smoking.

A backbench debate was held on Jan 18 in the UK Parliament as the tenth session of the Conference of the Parties to the Framework Convention on Tobacco Control (COP10) is scheduled to take place in Panama from February 5 to 10, and the UK will be sending a delegation.

 

The debate, initiated by Members of Parliament Andrew Lewer, Mr. Virendra Sharma, and Martyn Day, aimed to challenge the WHO's opposition to e-cigarettes, focusing on the regulation of e-cigarettes in the UK, the World Health Organization (WHO), and the differing stances of the organization and the UK government on e-cigarettes.

 

The WHO for a long time has been committed to controlling the use of tobacco and nicotine products, particularly e-cigarettes. According to reports from December 14, 2023, the organization emphasized the need for urgent action to control e-cigarettes, aiming to protect children and non-smokers while minimizing health risks to the public. The WHO pointed out that the nicotine present in e-cigarettes is highly addictive and harmful to health.

 

During the debate on Thursday, Member of Parliament Andrew Lewer argued against this perspective. He cited research from Cancer Research UK, stating that "it's not nicotine but the chemicals produced during the combustion of tobacco that cause lung cancer."

 

Based on this theoretical finding, MP Andrew Lewer throughout the debate addressed vaporized e-cigarettes as "tobacco harm reduction products," aligning with the broader direction of the UK government's tobacco control policy. He insisted on two central arguments. First, new tobacco products, including vaporized e-cigarettes, should not be subject to the same tax rates as traditional cigarettes. Second, flavored vaporized e-cigarettes should not be banned. He argued that without tax (price) incentives and flavor differentiation compared to traditional cigarettes, there would be little motivation for people to quit smoking.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Andrew Lewer, a member of parliament who spoke in the backbench debate on January 18th | Image source: 2FIRSTS

 

In addition to urging the UK delegation to maintain its stance on the smoking cessation role of e-cigarettes in international conferences, Andrew Lewer also questioned the entire WHO institution during the debate and raised the issue of whether the UK should review the scale of its donations to the organization. This is because the UK is currently one of the largest funders of the WHO, and there is a need to ensure that "taxpayers' money is well utilized."

 

Later in the debate, co-initiator Virendra Sharma stated, "COP10 and WHO should not make it harder for those who want to quit smoking with e-cigarettes." Therefore, policies that excessively regulate e-cigarettes, heated tobacco, and oral nicotine pouches are worthy of debate.

 

He also mentioned that although the UK is a global leader in tobacco harm reduction policies, it can still learn from other countries' successful experiences in using new nicotine products to control smoking. He cited Japan and Sweden as examples where heated tobacco and oral snus significantly reduced smoking rates. There are better ways for the UK to achieve a better outcome through compromise.

 

Labour politician and Member of Parliament for Bristol South, Karin Marguerite Smyth, also participated in the debate. After expressing anticipation for the UK delegation's participation in the treaty conference and conveying the country's voice, she mentioned that many MPs have received letters from constituents inquiring about e-cigarettes and smoking because it will be a central topic at COP10. Voters are concerned about whether this conference will change the future use of e-cigarettes by British citizens. She asked the Minister of Public Health if there are plans to include other nicotine products in the upcoming government bill's regulatory process.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Virendra Sharma | Image source: 2FIRSTS

 

The responsibility of responding to inquiries in this debate fell on Dame Andrea Jacqueline Leadsom, who has taken office as the Deputy Minister of Public Health, Start for Life, and Primary Care since November 2023. She expressed opposing views to some points raised by the aforementioned MPs.

 

Using her own experience of teenage smoking and the challenging process of quitting, she stated that claiming nicotine is entirely harmless is "wrong" and reiterated the addictive nature of nicotine. She also raised some questions, mentioning that flavors like cherryade and bubble-gum are not designed for adults. These flavors and packaging resembling little Coke bottles or brightly colored like bubble-gum are clearly "aimed at children." The fact that e-cigarettes are placed next to candies, sold conveniently at pocket-money prices is concerning. Therefore, she urged MPs not to "naively look at this issue" and emphasized that only strong enforcement measures can ensure that e-cigarettes are not sold to minors.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Dame Andrea Jacqueline Leadsom who spoke in the back seat debate on January 18th | Image source: 2FIRSTS

 

Regarding the upcoming COP10, she described the UK as a "unique case" on the issue of e-cigarettes and stated that the country will present its position at the conference, emphasizing that e-cigarettes are a crucial tool to help adults quit smoking. "But as for whether there should be a change in the current level of donations to the WHO, the UK government tends to maintain the existing level." She concluded by stating that she will provide a statement to the Parliament after COP10 to update on the proceedings.

 

E-cigarettes in Backbench Debates

 

This is not the first time tobacco (or novel tobacco) has appeared in backbench debates in the UK.

 

Backbench debates, also known as Westminster Hall debates, allow MPs to raise local or national issues and receive responses from government ministers.

 

According to incomplete statistics, in June 2020, government MPs revolted against the ban on people importing liquid nicotine for e-cigarettes; on November 3, 2022, the House of Commons debated the Independent Review of Smokefree 2030 policies; and earlier this week, there was another debate on e-cigarettes. On January 16, a debate hosted by Conservative MP Peter Gibson discussed issues related to illicit (gray) market vaping products and underage illegal vaping.

 

The UK's stance on novel tobacco, especially e-cigarettes, has consistently differed from the WHO's perspective. The UK government has been supportive of e-cigarettes as an alternative to reduce the harm of smoking. According to the UK government's viewpoint, e-cigarettes can help smokers quit, and their harm is much lower than that of traditional tobacco products.

 

A report from Policy Exchange indicates that smoking has a significant impact on the economy, and reducing smoking rates not only improves health conditions and alleviates the burden on the national health service but also promotes productivity and economic growth.

 

2FIRSTS will continue to monitor the upcoming Conference of the Parties to the WHO Framework Convention on Tobacco Control (COP10) in Panama, as well as developments in UK tobacco control policies and regulations for both traditional and novel tobacco products.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Smoore’s first-half 2026 revenue rose 19.9%, but the results revealed growing structural risks beneath the headline growth. Heat-not-burn contributed about 61% of incremental revenue and remains driven largely by one core customer, while traditional vaping markets diverged, own-brand growth slowed and China enterprise revenue declined further. Gross profit and adjusted profit lagged revenue growth, while second-quarter revenue growth slowed to about 1.9%, putting greater focus on the quality, concentration and sustainability of Smoore’s expansion.
Capital Markets
Aug.20
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
EU Trade Department Faces Scrutiny Over Contacts With Tobacco Industry
EU Trade Department Faces Scrutiny Over Contacts With Tobacco Industry
European Ombudswoman Teresa Anjinho has opened an inquiry into how the European Commission’s Directorate-General for Trade handles interactions with the tobacco industry. The case follows a complaint from a civil society organisation that alleges regular, unnecessary and non-transparent contacts between DG TRADE and tobacco industry representatives, raising questions over compliance with the EU’s obligations under the WHO Framework Convention on Tobacco Control. The inquiry remains ongoing, and the Ombudswoman has not reached any finding of maladministration.
Aug.24